Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?
Krystal Biotech, Inc. (NASDAQ:KRYS) has something most biotech companies spend years trying to achieve: a drug that works, is approved, and is already generating meaningful revenue.





